Scalpa Ex-CEO to Be Sentenced April 9

Former Scalpa chief Bryce Cleveland faces sentencing after the company pled guilty to charges over unapproved skincare devices and drugs.

Updated on Nov. 18, 2026 in Beauty

Scalpa Ex-CEO to Be Sentenced April 9

Bryce Cleveland, former President and CEO of Scalpa, is scheduled for a sentencing hearing on April 9, 2027, at 11:00 a.m. Scalpa pled guilty in July 2026 to three charges related to selling skincare products not approved by the FDA.

Why it matters

The case centers on the marketing of products such as ScalpaJECT Hyaluronic Acid, Hyaluron Pen and Scalpatox, which regulators did not approve for sale. Cleveland's sentence will show how federal courts treat unapproved beauty devices and drugs sold to consumers.

Scalpa pled guilty in July 2026 to three charges tied to selling unapproved skincare products, with the company incorporated in Arizona in 2015. The sentencing hearing for Cleveland is set for April 9, 2027, and the full extent of penalties remains undetermined until the court rules.

The players

Bryce Cleveland

Former President and CEO of Scalpa, a skincare company whose products were the subject of the FDA-related charges.

Scalpa

Arizona for-profit corporation incorporated in 2015 that marketed medical devices and drug products sold as skincare treatments.

The details

Prosecutors allege that between 2018 and December 2020, Cleveland devised a scheme to enrich himself by marketing and delivering devices he falsely represented were not subject to FDA regulation. The filing also alleges he introduced the unapproved drug Scalpatox into commerce.

Timeline

  1. Between 2018 and December 2020: alleged period of Cleveland's scheme to market unapproved devices.

  2. July 2026: Scalpa pled guilty to three charges.

  3. April 9, 2027, 11:00 a.m.: sentencing hearing for Bryce Cleveland.

Industry Dynamics

The prosecution applies FDA approval requirements under the Federal Food, Drug, and Cosmetic Act to aesthetic injectables and devices sold outside traditional clinical settings. It signals continued federal enforcement against beauty products that claim regulatory exemption without approval.

Consumers buying injectable or device-based skincare products can check whether they carry FDA clearance or approval before purchase. Products marketed as exempt from FDA regulation may not have undergone safety review.

The takeaway

Before buying injectable or device-based skincare, verify FDA clearance or approval rather than relying on a seller's claim of exemption. Unapproved products can carry risks that are not disclosed to buyers.

What happens next

Bryce Cleveland's sentencing hearing is scheduled for April 9, 2027, at 11:00 a.m. in the U.S. District Court in Abingdon, Virginia.

Further reading

Explore more Beauty coverage for context on skincare regulation and product safety.

More information

Review the victim information page for United States v. Bryce Cleveland on the Department of Justice site.

Source note: This article includes information reported by The United States Department of Justice.